Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
News|Articles|April 3, 2025
Q1 2025: A recap of the top headlines and interviews
View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.
Advertisement
Advertisement
As we move into the second quarter of 2025, Q1 brought several treatment regulatory updates and clinical trial results to help better take care of pediatric patients across the globe.
Related to this article
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.
Learn how to distinguish true ADHD from anxiety, trauma, sleep issues, or substance use by tracing symptoms back to childhood across settings and impairment.
NHIS data show the share of US children aged 5 to 17 years ever diagnosed with ADHD climbed from 9.9% in 2019 to 13.8% in 2025.
Lower maternal PlGF in the third trimester was tied to child ADHD in a University of Iowa cohort, independent of preeclampsia and FGR.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Advertisement
Advertisement